Ventilator-Associated Pneumonia (VAP)

Definition

Incidence and Significance

• Occurs in up to 15–20% of mechanically ventilated patients (older studies); more recent NHSN data show <4% per ventilation episode due to widespread bundle adoption
• Mortality ranges 30–70%; attributable mortality is debated but remains clinically significant
• Increases ICU length of stay, duration of mechanical ventilation, and hospital costs
• At least 55% of cases are preventable
• Compared to patients without VAP: 2.4% mortality vs. 10.5% mortality in those with VAP (Srinivasan et al., 2009)

Pathogenesis and Risk Factors

Pathophysiological Mechanisms

1. Bypass of natural airway defenses — The endotracheal tube (ETT) bypasses the cough reflex, mucociliary clearance, and epiglottic protection
2. Microaspiration — Contaminated oropharyngeal and gastric secretions leak around the ETT cuff into the lower respiratory tract
3. Biofilm formation — Organisms colonize the inner surface of the ETT and form biofilms; fragments are dislodged into the lungs with each breath
4. Impaired mucociliary clearance — Sedation, paralysis, and positive-pressure ventilation reduce secretion clearance
5. Altered gastric microbiome — Acid-suppressive therapy allows bacterial overgrowth; organisms can ascend to the oropharynx and trachea

Patient Risk Factors

Classification: Early vs. Late-Onset VAP

Diagnosis

Clinical Criteria (modified CPIS — Clinical Pulmonary Infection Score)

1. New or progressive infiltrate on chest radiograph
2. Clinical signs of infection: fever/hypothermia, leukocytosis/leukopenia, purulent secretions
3. Positive microbiological culture from lower respiratory tract specimens

Microbiological Sampling

Clinical Pearl: Tracheal aspirates are preferred over BAL (IDSA weak recommendation), but BAL is more specific for true lower respiratory tract infection. An invasive strategy limits antibiotic overuse.

Differential Diagnosis

• ARDS, pulmonary edema, atelectasis, pulmonary embolism, drug-induced pneumonitis, pleural effusion

Prevention — VAP Bundle

Core Bundle Components (IHI VAP Bundle)

1. Head-of-Bed (HOB) Elevation ≥30–45°

• Reduces aspiration of gastric and oropharyngeal secretions
• One study showed 70% reduction in VAP compared to supine position
• Should be maintained at all times unless medically contraindicated (e.g., spinal precautions, hemodynamic instability)

2. Daily Sedation Interruption (Spontaneous Awakening Trial — SAT)

• "Sedation vacation" each day: stop all sedatives, assess patient orientation
• Reduces total sedation duration, promotes earlier extubation
• Must be followed immediately by Spontaneous Breathing Trial (SBT)

3. Spontaneous Breathing Trial (SBT)

• Daily assessment for readiness to wean/extubate
• Criteria: underlying disease improved, FiO₂ ≤0.5, PEEP <8 cmH₂O, SpO₂ >88%, hemodynamically stable, adequate cough
• SAT + SBT synergy decreases mechanical ventilation days significantly

4. Oral Decontamination with Chlorhexidine

• Chlorhexidine (0.12–0.2%) mouth rinse every 2–4 hours
• Reduces oral bacterial colonization (especially dental plaque)
• Meta-analyses of unblinded studies show ~30% reduction in VAP; double-blind studies show attenuated benefit — evidence is evolving
• Some concern about possible increased VAP events and mortality on reanalysis (Murray & Nadel) — use is still routine but under scrutiny

5. Peptic Ulcer/GI Stress Ulcer Prophylaxis

• Acid-suppressive agents (H₂ blockers, PPIs) increase gastric bacterial overgrowth → risk of VAP
• Sucralfate is preferred in low-risk patients as it provides mucosal protection without raising gastric pH
• Reserve PPIs/H₂ blockers for high-risk patients (coagulopathy, history of GI bleeding, mechanical ventilation >48h)

6. Deep Vein Thrombosis (DVT) Prophylaxis

• Standard bundle component; reduces PE; heparin or LMWH unless contraindicated

Additional Bundle Elements

Subglottic Secretion Drainage (SSD)

• Specialised ETTs with a suction port above the cuff allow continuous or intermittent aspiration of secretions pooled above the cuff
• Three large meta-analyses demonstrate significant VAP reduction (~50% reduction in early-onset VAP)
• Also reduces ICU length of stay and duration of mechanical ventilation
• Recommended as a routine bundle component in high-risk patients

Ventilator Circuit Management

• Do NOT change circuits routinely — frequent changes increase VAP risk by introducing contaminated secretions into the airway
• Change circuits only when visibly soiled or mechanically faulty
• Drain condensate from tubing every 2–4 hours and before repositioning the patient — without disconnecting the circuit
• Use inline (closed) suction catheters to avoid circuit disconnection during ETT suctioning

ETT Cuff Pressure Monitoring

• Maintain cuff pressure >20 cmH₂O (ideally 25–30 cmH₂O) to prevent microaspiration around the cuff
• Routine monitoring; avoid over-inflation (>30 cmH₂O → mucosal ischemia)
• Tapered/polyurethane cuffs reduce vertical microfold formation and microaspiration

Avoid Nasal Intubation

• Nasal ETTs and nasogastric tubes increase risk of sinusitis → secondary VAP
• Orotracheal intubation is preferred

Hand Hygiene

• Strict handwashing and glove use before/after handling ventilator circuits and airway secretions — the simplest and least expensive intervention

Early Mobilization

• Reduces duration of ventilation, sedation requirements, and VAP risk
• Early physical therapy is an integral component of modern ICU care

Selective Digestive Decontamination (SDD)

• Consists of: (a) short course of systemic antibiotics (cefotaxime/fluoroquinolone) + (b) topical nonabsorbable antibiotics to mouth and stomach (aminoglycoside + polymyxin E + amphotericin B)

• 40 RCTs and 8 meta-analyses all show significant VAP reduction and improvement in ICU mortality

• Not widely adopted in the United States due to concern about selection of antimicrobial-resistant organisms (especially in high-endemicity settings)
• More accepted in Europe

Noninvasive Ventilation (NIV)

• HFNC and BiPAP/NIV should be used whenever possible to avoid intubation entirely — eliminating the ETT eliminates the primary VAP risk
• NIV preferred in: COPD exacerbation, acute pulmonary edema, post-extubation failure
• Avoid in: high aspiration risk, excessive secretions, facial trauma, haemodynamic instability

Early Tracheostomy

• Lower VAP risk than prolonged ETT (biofilm burden reduced, easier secretion clearance)
• Shorter mechanical ventilation and ICU stay
• Indicated when prolonged ventilation anticipated (>2 weeks) or failed extubation expected

Treatment of VAP

General Principles

1. Do not delay treatment — start empirical antibiotics immediately after obtaining cultures; delay increases mortality
2. De-escalation — after 48–72 hours, narrow antibiotics based on culture and sensitivity results
3. Target treatment duration: 7 days (IDSA/ATS guideline) — equivalent efficacy to 14 days with less resistance selection

Empiric Antibiotic Therapy

Early-onset VAP (<72 hours, no MDR risk factors)

• Monotherapy is adequate
• Ceftriaxone OR ampicillin-sulbactam OR levofloxacin
• Add vancomycin or linezolid if known MRSA colonisation or recent MRSA history

Late-onset VAP (>72 hours or MDR risk factors)

• Two-drug combination covering MDR gram-negatives + MRSA:
  • Anti-pseudomonal β-lactam: Piperacillin-tazobactam OR cefepime OR ceftazidime OR meropenem/imipenem (if ESBL/carbapenem concern)
  • PLUS anti-MRSA agent: Vancomycin OR linezolid
  • Add ciprofloxacin if high local MDR gram-negative burden
• Adjust based on local ICU antibiogram

Barash Clinical Anesthesia regimen summary:

Specific Pathogens and Agents

Diagnostic Refinement and De-escalation

• Repeat cultures at 48–72 hours
• If cultures negative and clinical improvement → discontinue antibiotics (avoid over-treatment)
• If cultures positive → narrow to the most targeted effective agent
• Biomarkers (procalcitonin, CRP) can support de-escalation decisions

Summary Table: VAP Prevention Bundle at a Glance

Key Exam Points

• VAP is defined as pneumonia developing ≥48 hours after mechanical ventilation
• Early VAP = antibiotic-sensitive organisms; Late VAP = MDR organisms (MRSA, Pseudomonas, Acinetobacter)
• The ETT is the single greatest risk factor — if you can avoid it, do so (use NIV)
• The VAP bundle works by synergy — no single component is sufficient alone
• Subglottic suctioning is one of the most evidence-based device-level interventions
• De-escalation at 48–72 hours is mandatory to limit antibiotic resistance
• Treatment duration: 7 days (not 14) per IDSA/ATS guidelines
• For late-onset VAP: always cover MRSA + MDR gram-negatives empirically until cultures return

Etomidate — MD Anaesthesia Long Answer

1. Introduction and History

2. Physicochemical Properties

3. Pharmacokinetics

Key Pharmacokinetic Points for Exam:

• Recovery from a single dose is by redistribution, not hepatic metabolism — therefore, single-dose recovery is NOT prolonged by hepatic disease
• In cirrhosis: volume of distribution doubles, clearance normal → elimination half-life doubles (but single-dose effect unchanged)
• In elderly patients: smaller initial volume of distribution and decreased clearance
• In haemorrhagic shock (pigs model): pharmacokinetics and pharmacodynamics unchanged — unique advantage over other IV agents
• Context-sensitive half-time is shorter than propofol, making it theoretically suitable for infusion — however, adrenal suppression prevents this

4. Mechanism of Action

1. Positive allosteric modulation (at clinical doses): Enhances GABA-A receptor sensitivity — a lower GABA concentration is required to activate the receptor
2. Direct activation/allosteric agonism (at supraclinical doses): Directly activates GABA-A receptor in the absence of GABA

5. Pharmacodynamics

A. Central Nervous System (CNS)

Key point for exam: Etomidate is the ONLY IV induction agent that paradoxically increases SSEP amplitude — all others decrease it.

B. Cardiovascular System (CVS)

• Minimal effect on heart rate, cardiac output, and SVR
• Does not depress baroreceptor function — reflex mechanisms remain intact
• Does not depress sympathetic nervous system
• Mild α₂-adrenoceptor stimulation → slight increase in blood pressure
• No histamine release
• Changes in HR, BP, cardiac output, and SVR are less than 10% — far superior to propofol, thiopentone, and ketamine (in haemodynamically compromised patients)
• Safe in:
  • Severe cardiac disease / low ejection fraction
  • Hypovolaemia and haemorrhagic shock
  • Trauma patients requiring RSI
  • Elderly and ASA III–IV patients

C. Respiratory System

• Minimal respiratory depression — does not trigger histamine release
• Brief period of hyperventilation on induction, sometimes followed by brief apnoea
• Net effect: slight ↑ PaCO₂ (~±15%), no change in PaO₂
• Ventilatory response to CO₂ is depressed but greater than after equipotent methohexital
• Laryngeal reflexes relatively preserved — useful for MAC sedation (airway reflexes maintained)
• Does not cause bronchospasm — safe in reactive airway disease

D. Endocrine System — Adrenocortical Suppression (Most Significant Adverse Effect)

• Etomidate inhibits 11β-hydroxylase (also called CYP11B1), the mitochondrial enzyme responsible for the final conversion of 11-deoxycortisol → cortisol (and 11-deoxycorticosterone → corticosterone)
• This blocks the final step in cortisol synthesis in the adrenal cortex
• Also inhibits cholesterol side-chain cleavage enzyme and 17α-hydroxylase

• A single induction dose can transiently suppress the HPA axis for 6–24 hours (some studies suggest up to 48 hours)
• Leads to decreased serum cortisol and aldosterone
• Continuous infusion: prolonged suppression — this caused the increased ICU mortality observed in the 1980s
• Contraindication: Continuous infusion in critically ill patients; relative contraindication in septic shock (debated — some RCTs show no harm from a single bolus, but practitioners avoid repeat dosing)
• Suggested mitigation: Pretreatment with dexamethasone (does not affect cortisol assays and covers adrenal axis)

6. Clinical Uses

7. Adverse Effects

Reducing Myoclonus:

• Priming with small dose of fentanyl, midazolam, or low-dose opioid before etomidate
• Use of lipid emulsion formulation (Etomidate-Lipuro)

8. Contraindications

9. Novel Etomidate Derivatives

10. Comparison with Other Induction Agents

11. Key Exam Points — Summary

1. Imidazole derivative — D(+) enantiomer; GABA-A receptor agonist
2. Dose: 0.2–0.3 mg/kg IV; onset in one arm-brain circulation (30–60 s)
3. Three-compartment kinetics; recovery by redistribution; hepatic ester hydrolysis
4. Unique advantage: Haemodynamic stability — HR, BP, CO unchanged; best choice in cardiac disease, haemorrhage, trauma
5. CNS: ↓ CBF by 34%, ↓ CMRO₂ by 45%, ↓ ICP by 50%, maintains/↑ CPP
6. Unique SSEP finding: Increases amplitude (all others decrease)
7. Mechanism of adrenal suppression: Inhibits 11β-hydroxylase → ↓ cortisol conversion
8. Adrenal suppression lasts 6–24+ hours after single dose; contraindicated as infusion
9. Myoclonus in up to 60% — not true epilepsy on EEG
10. Propylene glycol vehicle causes pain on injection and thrombophlebitis — use lipid emulsion to reduce
11. High PONV — always prescribe antiemetics
12. ECT: Proconvulsant, prolongs seizure — no dose-dependent seizure inhibition (unlike propofol/methohexital)
13. Use dexamethasone pretreatment in high-risk patients to blunt adrenal suppression